Skip to main content
Premium Trial:

Request an Annual Quote

Waters Q3 Revenues Rise 11 Percent

NEW YORK – Waters reported on Tuesday that its revenues in the third quarter were up 11 percent.

The firm posted revenues of $659.2 million in Q3 compared to $593.8 million in Q3 2020 and beating the average Wall Street estimate of $656.5 million. Waters said that foreign currency translation boosted sales growth by less than 1 percent in the quarter.

The company said that sales in the pharmaceutical market increased 16 percent, sales in the industrial market increased 9 percent, and sales in the academic and government markets decreased 9 percent.

In a statement, Waters CEO Udit Batra said the company saw double-digit growth in instrument sales and recurring revenues.

The Milford, Massachusetts-based company posted a Q3 net profit of $161.2 million, or $2.60 per share, compared to a net profit of $126.8 million, or $2.03 per share, for Q3 2020. On a non-GAAP basis, Waters had EPS of $2.66, beating analysts' average estimate of $2.35.

The firm's R&D spending was up 20 percent year over year to $42.0 million from $35.0 million, while SG&A costs were up 13 percent to $152.5 million from $135.4 million.

The company ended the quarter with $655.2 million in cash, cash equivalents, and investments.

Waters provided a full-year 2021 guidance of revenue growth in the range of 15 percent to 16 percent, and non-GAAP EPS between $10.94 and $11.04. It expects Q4 2021 sales growth between 5 percent and 7 percent and non-GAAP EPS between $3.40 and $3.50.

In Tuesday morning trading on the New York Stock Exchange, shares of Waters were down 4 percent to $350.26.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.